All In Biotech

Drug Trial Radar · NCT05550207

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 31, 2022

Primary completion

Nov 27, 2024

Study completion Nov 27, 2024

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.

Conditions

  • Migraine

Interventions

  • AXS-07 (meloxicam-rizatriptan)Drug

    AXS-07 tablets, taken orally for the acute treatment of migraine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with headache pain reliefTime frame: Hour 2 following dose administration
  2. Percentage of subjects with absence of the Most Bothersome SymptomTime frame: Hour 2 following dose administration

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Colton, California

  • Clinical Research Site

    Fullerton, California

  • Clinical Research Site

    La Jolla, California

  • Clinical Research Site

    Los Angeles, California

  • Clinical Research Site

    Sherman Oaks, California

  • Clinical Research Site

    Stamford, Connecticut

  • Clinical Research Site

    DeLand, Florida

  • Clinical Research Site

    Hallandale, Florida

  • Clinical Research Site

    Hollywood, Florida

  • Clinical Research Site

    Miami, Florida

  • Clinical Research Site

    Ormond Beach, Florida

  • Clinical Research Site

    Oviedo, Florida

  • Clinical Research Site

    Pensacola, Florida

  • Clinical Research Site

    Winter Park, Florida

  • Clinical Research Site

    Stockbridge, Georgia

  • Clinical Research Site

    Avon, Indiana

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    North Dartmouth, Massachusetts

  • Clinical Research Site

    Las Vegas, Nevada

  • Clinical Research Site

    Albuquerque, New Mexico

  • Clinical Research Site

    The Bronx, New York

  • Clinical Research Site

    Williamsville, New York

  • Clinical Research Site

    Philadelphia, Pennsylvania

  • Clinical Research Site

    Charleston, South Carolina

  • Clinical Research Site

    Knoxville, Tennessee

  • Clinical Research Site

    Nashville, Tennessee

  • Clinical Research Site

    Cypress, Texas

  • Clinical Research Site

    Sugar Land, Texas

  • Clinical Research Site

    Salt Lake City, Utah

  • Clinical Research Site

    Charlottesville, Virginia

  • Clinical Research Site

    McLean, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.